跳至主要内容
临床试验/NCT02636738
NCT02636738终止不适用

A Prospective, Multicenter, Single-arm, Non-controlled Study to Evaluate The Safety and Utility of VelaTM XL Thulium Laser in Cutting And Hemostasis For Gastrointestinal Epithelial Neoplasia In Chinese Population

Boston Scientific Corporation2 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2016年6月6日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
2
试验地点
2
主要终点
Technique success

研究概览

简要总结

Prospective, multicenter, single-arm, non-controlled, 60 subjects enrolled and 14 days follow up for evaluate the safety and utility of VelaTM XL thulium laser.

详细描述

This study aimed to evaluate the safety and utility of VelaTM XL thulium laser in cutting and hemostasis for gastrointestinal epithelial neoplasia in Chinese population.

Vela China study will enroll at least 60 patients. Follow up points are 72 ±3 hours post procedure, 7±2 days post procedure, 14 days(±2 days) post procedure.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Willing and able to provide written informed consent to participate in the study and comply with the study procedures.
  • Diagnosed as gastrointestinal epithelial neoplasia and admitted to hospital for gastrointestinal ESD procedure.
  • EUS and/or CT are performed to confirm the absence of regional lymph node or distant metastasis.

排除标准

  • Endoscopic techniques or treatment are contraindicated.
  • Requirement for anticoagulation that cannot be safely stopped at least 7 days prior to the procedure.
  • Based on doctor's evaluation, the patient's medical condition doesn't fit for this study.

结局指标

主要结局

Technique success

时间窗: 1 hour

The procedure is mostly completed solely at one ESD procedure by VelaTM XL thulium laser, only if the direction of the laser could not be adjacent to the target, endoscopy knives will be assisted. The technique success rate will be calculated by the ratio of operation success subjects to total enrolled subjects.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
不适用
Renuvion Dermal System for Dermal ResurfacingWrinkleRhytides
NCT04185909Apyx Medical55
已完成
不适用
A prospective, controlled, multicentre non-interventional study of parenteral nutrition within the oncological outpatient careC00-C97Malignant neoplasms
DRKS00010078GHD GesundHeits GmbH Deutschland123
进行中(未招募)
1 期
A phase 3 study to compare efficacy and safety of masitinib with placebo in the patients with primary progressive or secondary progressive multiple sclerosis without relapse.Patients with primary progressive or secondary progressive multiple sclerosis without relapseMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063401Term: Primary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2021-000639-30-ESAB Science800
终止
不适用
A Prospective, Open Label, Multicenter Trial for Evaluating the Efficacy of Treating and Managing Wounds in Elderly Population in Specialized Nursing Facilities Using RD1Venous Leg UlcerTrauma InjurySkin TearChronic UlcerPressure UlcerDiabetic Foot Ulcer
NCT04577183RedDress Ltd.13
进行中(未招募)
1 期
A 24-month clinical study to evaluate whether the drug everolimus in combination with the drug cyclosporine or the drug tacrolimus can be safely and effectively used in liver transplant patients from 1 month to less than 18 years.Paediatric liver transplant recipients with age equal/greater to 1 month and younger than 18 years.MedDRA version: 14.1Level: LLTClassification code 10024716Term: Liver transplantationSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2011-003069-14-ITOVARTIS FARMA75